Filed: November 20, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner,

v.

YEDA RESEARCH & DEVELOPMENT CO. LTD.

Patent Owner.

Case IPR2015-00644

Patent No. 8,399,413

UPDATED LIST OF PATENT OWNER'S EXHIBITS

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner submits the following current exhibit list.

Exhibit No.	Description
2001	Teva Provides Update on Forte Trial (July 7, 2008)
2002	Franscisco J. Quintana et al., *Systems Biology Approaches for the Study of Multiple Sclerosis*, 12 J. Cellular & Molecular Med. 1087 (2008)
2003	David Virley, *Developing Therapeutics for the Treatment of Multiple Sclerosis*, 2 J. Am. Soc. Experimental Neurotherapeutics 638 (Oct. 2005)
2004	Manuel A. Friese et al., *The Value of Animal Models For Drug Development in Multiple Sclerosis*, 129 Brain 1940 (2006)
2005	Copaxone Prescribing Information (Jan. 2014)
2006	Dvora Teitelbaum et al., *Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide*, 1 Eur. J. Immunology 242 (1971)
2007	Jill Conner, *Glatiramer Acetate and Therapeutic Peptide Vaccines for Multiple Mclerosis*,1 J. Autoimmun. & Cell Responses 3 (2014)
2008	Copaxone, Physicians Desk Reference 3231 (62 ed. 2008)
2009	Wiebke Schrempf and Tjalf Ziemssen, *Glatiramer Acetate: Mechanisms of Action In Multiple Sclerosis*, 6 Autoimmun. Rev. 469 (2007)
2010	V.Wee Yong, *Differential Mechanisms of Action of Interferon-β and Glatiramer Acetate in MS*, 59 Neurology 802 (2002)
2011	Suhayl Dhib-Jalbut, *Mechanisms of Action of Interferons and Glatiramer Acetate in Multiple Sclerosis*, 58 Neurology S3–9 (Supp. 4 2002)
2012	O. Neuhaus et al., *Pharmacokinetics and Pharmacodynamics of the Interferon-Betas, Glatiramer Acetate, and Mitoxantrone in Multiple Sclerosis*, 259 (1-2) J. Neurol. Sci. 27-37 (2007)

2013	Oded Abramsky *et al.*, *Effect Of A Synthetic Polypeptide (COP 1) on Patients with Multiple Sclerosis and With Acute Disseminated Encephalomyelitis*, 31 J. Neurol. Sci. 433 (1977)
2014	Murry B. Bornstein et al., *Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results*, 105 Tran. Am. Neurol. Assoc. 348 (1980)
2015	Murry B. Bornstein *et al.*, *Multiple Sclerosis: Trial of a Synthetic Polypeptide*, 11 Annals Neurol. 317 (1982)
2016	Murry B. Bornstein et al., *A Pilot Trial of COP 1 in Exacerbating-Remitting Multiple Sclerosis*, 13 New Engl. J. Med. 408 (1987)
2017	Sage Journals, Table of Contents, http://msj.sagepub.com/content/14/1_suppl.toc (Sept. 2008)
2018	Massimo Filippi *et al.*, *Effects of oral glatiramer acetate on clinical and MRI monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo- controlled study*, http://neurology.thelancet.com (Jan. 20, 2006)
2019	Yuval Ramot *et al.*, *Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate, Copaxone1, and TV-5010, Protiramer) in Rats and Monkeys*, 40 Toxicol. Pathways 40 (2012)
2020	U.S. Patent Application No. 2007/0161566 A1
2021	T. Ziemssen et al., *Risk-benefit assessment of glatiramer acetate in multiple sclerosis*, 24(13) Drug Safety 979 (2001)
2022	Teva News Release, *Phase III Data Published in Annals of Neurology Show That a Higher Concentration Dose of Glatiramer Acetate Given Three Times a Week Reduced Annualized Relapse Rates in the Treatment of Relapsing-Remitting Multiple Sclerosis* (July 1, 2013)
2023	Omar Khan *et al.*, *Three Times Weekly Glatiramer Acetate in Relapsing–Remitting Multiple Sclerosis*, 73 Annals Neurol. 705 (2013)
2024	Teva Press Release, *Teva Reports First Quarter 2015 Results* (April 30, 2015)
2025	Kate McKeage, *Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review*, CNS Drugs (April 24, 2015)

2026	K.P. Johnson et al., *Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase I11 multicenter, double-blind, placebo-controlled trial*, 45 Neurology 1268 (1995)
2027	Intentionally left Blank
2028	G. Comi, *Forte: Results from a phase II, 1-year, Randomized, Double-blind, Parallel-Group, Dose Comparison Study with Glatiramer Acetate in Relapsing-remitting Multiple Sclerosis*, Presented at World Congress on Treatment and Research in Multiple Sclerosis: 2008 Joint Meeting of the American, European, and Latin America Committees on Treatment and Research in Multiple Sclerosis, San Raffaele, Italy (ACTRIMS, ECTRIMS, LACTRIMS) (2008)
2029	Jerry S. Wolinsky *et al*., GLACIER: *An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis*, 4 Multiple Sclerosis and Related Disorders 370 (2015)
2030	C. Farina *et al*., *Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells*. 124 Brain 705 (2001).
2031	PRA, *Multiple Sclerosis: Transform Your Clinical Trial with PRA* (2012) (Peroutka Dep. Ex. 4)
2032	Opinion, *Endo Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc*., No. 11-cv-00717, Document 226 (Jan. 28, 2014) (Peroutka Dep. Ex. 6)
2033	Donna Oksenberg et al., *A single amino acid difference confers major pharmacological variation between human and rodent 5-HT-1B receptors*, 360 Nature 161 (1992) (Peroutka Dep. Ex. 9)
2034	Shalit et al., *Copolymer-1 (Copaxone®) induces in non-immunologic activation of connective tissue type mast cells*, 97(1) J. Allergy And Clinical Immunology 345 (1996) (Peroutka Dep. Ex. 12)

2035	Order, *Endo Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc*., No. 11-cv-00717, Document 310 (Apr. 8, 2014) (Peroutka Dep. Ex. 15)
2036	M. Fridkis-Hareli et al., *Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules*. . 15;162(8):4697-704. (Apr. 1999)
2037	Notice of Abandonment APN 11/651,212 (03-09-10)
2038	B. Meibohm & H. Derendorf, *Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling*.35(10) , 401-413 (1997)
2039	P.H. Lambert & P.E. Laurent, *Intradermal vaccine delivery: will new delivery systems transform vaccine administration?* 26(26) Vaccine, 3197-208 (2008)
2040	G. Glenn et al., *Transcutaneous immunization and immunostimulant strategies*, 23(4) Immunology And Allergy Clinics Of N. Am., 787-813 (2003)
2041	C.D. Partidos et al., *Immunity under the skin: potential application for topical delivery of vaccines*, 21Vaccine 776 (2003)
2042	C. Ghose et al., *Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice*, 75 Infection & Immunity 2326 (2007)
2043	G. Glenn et al., *Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge*, 161(7) J. Immunology 3211 (1998)
2044	R. Aharoni et al., *Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1*, 97 Proc. Nat'l Acad. Sci. U.S.A., 11472 (2000)

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.